Recent industry reports have highlighted past and projected rapid expansion in the DNA diagnostics and genomics markets, driven by liquid biopsies, direct-to-consumer testing, and personalized ...
With the MiSeq™ i100 Series, Illumina continues to set the highest standards.Advancements in system design, sequencing chemistry, and data analysis deliverthe simplest, fastest benchtop sequencing and ...
Illumina, Inc. (NASDAQ:ILMN), a leader in the life sciences tools and services industry with a market capitalization of $15.6 billion, has been navigating a challenging landscape marked by ...
Proteomics enables the observation of direct cellular function to gain insights on protein-driven disease traits. (Image Credits: Pixabay) Illumina, Inc. on Monday announced that it will present ...
Illumina, Commercial Metals and Newmont stand out as brokers boost ratings amid inflation concerns and shifting economic signals.
Program aims to address key barriers to genomic sequencing in-country SAN DIEGO, Nov. 13, 2023 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based ...
Illumina, Inc. has announced that scientists at the Company have completed sequencing the genomes of an anonymous African Trio (Yoruba from Ibadan, Nigeria) using the company's Genome Analyzer ...
Bengaluru: Medical equipment maker Illumina announced on Wednesday its new series of smaller, low-cost benchtop gene sequencers, to make sequencing accessible to more research and testing labs. New ...
Illumina, Inc. has announced the immediate availability of a transformative addition to its industry-leading next-generation sequencing portfolio with the launch of the NextSeq 500 System. The new ...
Discover how personal genomics is transforming healthcare with Illumina's genetic sequencing services and evolving costs. So far, personalized genomics make up just a small fraction of Illumina's ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback